Veeva Systems Inc. (VEEV) News
Filter VEEV News Items
VEEV News Results
|Loading, please wait...|
VEEV News Highlights
- VEEV's 30 day story count now stands at 51.
- Over the past 23 days, the trend for VEEV's stories per day has been choppy and unclear. It has oscillated between 1 and 12.
- DOW, CRM and APP are the most mentioned tickers in articles about VEEV.
Latest VEEV News From Around the Web
Below are the latest news stories about Veeva Systems Inc that investors may wish to consider to help them evaluate VEEV as an investment opportunity.
Veeva Systems (NYSE: VEEV) today announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic conditions, has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, and data cleaning for their upcoming study on the detection of wound infections.
Investing in stocks? Use this 3-step routine to help you stay profitable and protected, particularly in troubled markets.
Veeva Systems' (VEEV) Development Cloud applications to aid in connected drug development.
Recently, after hours on September 1, Veeva Systems (NYSE: VEEV) reported excellent earnings and despite having upped both fiscal 2022 revenue and EPS guidance, investors reacted poorly with the stock dropping 5% the day after earnings were released. The stock has drifted down another 5% to close at $299.74 on...
Emmes and Veeva Systems (NYSE: VEEV) today announced that Emmes is standardizing on Veeva Development Cloud applications across functional areas to enable greater speed and compliance. The company will use applications in Vault Clinical, Vault Quality, and Vault Safety suites to establish a technology foundation for delivering clinical research and pharmacovigilance services to its global customers.
Veeva has found dominance in its niche and its continual product expansion in a growing industry could result in sustained growth.
Veeva Systems (NYSE: VEEV) provided its fiscal 2022 second-quarter update earlier this month. In this Motley Fool Live video, recorded on Sept. 8, Fool contributors Keith Speights and Brian Orelli discuss what investors should like about Veeva's latest results. Keith Speights: Brian, we cover earnings during the thick of earnings season, and that's passed now.
Veeva Systems (VEEV) is a cloud-based software as a service (SaaS) company that targets the life sciences industry. The platform helps drugmakers develop drugs more efficiently, market the drugs to doctors, and maintain compliance with regulations. Veeva has seen consistently strong top-line growth in the past decade. In 2021, revenue grew by 32.7%, with 72.1% gross margins and 25.8% profit margins. However, the stock trades at a premium of 114.6 times earnings. As we continue to approach October, a historically volatile period for the stock market, we place a neutral rating on Veeva Systems because its high multiple may make it vulnerable to unwanted drawdowns.
Technology-based healthcare stocks like Henry Schein (HSIC), Veeva Systems (VEEV) and BD (BDX) are expected to continue their rally over the next few months.
CRM in Pharma and Biotech Software Market Receives a Rapid Boost in Economy due to High Emerging Demands by Forecast to 2026 | Veeva Systems, Aurea, Oracle, AKA Enterprise Solutions
CRM in Pharma and Biotech Software Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market. This is a